Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mikel Daniels

Podiatrist Owings Mills, MD Doctor of Podiatric Medicine

NPI 1730185091 CMS profile 305898

20 Crossroads Dr, Ste 14, Owings Mills, MD 21117

Open in the dashboard

General payments

$814

38 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mikel Daniels of Owings Mills, MD is reported in the CMS Open Payments database as having received $814 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184 4
2024 General $148 3
2022 General $32 2
2021 General $60 3
2020 General $161 8
2019 General $229 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mikel Daniels
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Mikel Daniels were reported at $184. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Mikel Daniels Podiatrist median Middle half National median
2019 $229 $196 $72–$601 $163
2020 $161 $118 $38–$335 $114
2021 $60 $169 $57–$573 $132
2022 $32 $220 $74–$782 $149
2023 $0 $208 $71–$635 $160
2024 $148 $237 $87–$681 $164
2025 $184 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $348 24 payments
  2. AxoGen $149 2 payments
  3. Allergan Inc. $88 4 payments
  4. Bioventus LLC $83 1 payment
  5. Organogenesis Inc. $31 1 payment
  6. Integra LifeSciences Corporation $30 1 payment
  7. Solventum Corporation $27 1 payment
  8. KCI USA, Inc $17 1 payment
  9. Hartmann USA, Inc. $15 1 payment
  10. Djo, LLC $14 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $814 38 payments
Products named General payments · program years 2019–2025
  1. Santyl $261 19 payments
  2. Oasis $93 1 payment
  3. Avance Nerve Graft $91 1 payment
  4. AxoGuard Nerve Connector $91 1 payment
  5. AXOGUARD NERVE PROTECTOR $91 1 payment
  6. Axoguard HA+ Nerve Protector $91 1 payment
  7. AXOGUARD NERVE CAP $91 1 payment
  8. DALVANCE $88 4 payments
  9. Stimrouter Implantable Kit $83 1 payment
  10. REGRANEX $48 4 payments
  11. Other $325 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

153

Median for Podiatry: 160

Drug cost

$1,736

Median for Podiatry: $2,368

Branded share of claims

17.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 19 $737
Gabapentin Generic 20 $236
Doxycycline Hyclate Generic 23 $158
Metronidazole Generic 11 $137
Levofloxacin Generic 18 $109
Tramadol Hcl Generic 23 $103
Nyamyc Nystatin Brand 11 $103
Ciprofloxacin Hcl Generic 12 $79
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 16 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 109 billing codes

Paid by Medicare

$650,642

Of which drugs: $2,894

Medicare patients

586

Average age 74

Services billed

6,680

297 women, 289 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Arthritis 53%
Chronic kidney disease 44%
Ischemic heart disease 42%
Depression 30%
Heart failure 29%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record